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Abstract
The objective of this study was to conduct an incremental cost-effectiveness analysis from the 
payer’s perspective in Singapore of 3 gestational diabetes mellitus screening strategies: universal, 
targeted, or no screening. A decision tree model assessed the primary outcome: incremental 
cost per quality-adjusted life year (QALY) gained. Probabilities, costs, and utilities were derived 
from the literature, the Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth 
cohort study, and the KK Women’s and Children’s Hospital’s database. Relative to targeted 
screening using risk factors, universal screening generates an incremental cost-effectiveness ratio 
(ICER) of $USD10 630/QALY gained. Sensitivity analyses show that disease prevalence rates 
and intervention effectiveness of glycemic management have the biggest impacts on the ICERs. 
Based on the model and best available data, universal screening is a cost-effective approach for 
reducing the complications of gestational diabetes mellitus in Singapore as compared with the 
targeted screening approach or no screening.
Keywords
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Introduction
With the worldwide obesity epidemic affecting Singapore, the prevalence of gestational diabetes 
mellitus (GDM) has steadily increased.1 GDM is associated with higher rates of both maternal 
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and fetal morbidity.2,3 For the mother, GDM increase the risks of preeclampsia, preterm labor, 
cesarean section, and maternal death. It also greatly increases the risk of developing type 2 dia-
betes mellitus.4-6 For the fetus, GDM increases the risks of macrosomia, shoulder dystocia, birth 
trauma, hypoglycemia, polycythemia, hyperbilirubinemia, renal vein thrombosis, and fetal 
death.1,4
These risks highlight the importance of properly screening and treating women at risk for 
GDM. Medical interventions for GDM patients reduce complication rates by as much as 60%.7-9 
However, which women to target for an oral glucose tolerance test (OGTT) diagnostic test, the 
primary screening strategy to identify GDM patients, remains an open question. For example, the 
National Institute for Health and Clinical Excellence (NICE) in the United Kingdom recom-
mends that screening should be limited only to pregnant women at high risk for developing 
GDM.4 Conversely, the United States practices universal screening of all pregnant women. 
Currently, Singapore uses a targeted approach where women identified as potentially high risk 
based on observable risk factors are given an OGTT to screen for GDM. However, they are con-
sidering revisiting this approach as a systematic review recently found that targeted screening 
using risk factors has a much lower sensitivity and specificity for diagnosing GDM compared 
with universal screening; many pregnant women who might benefit from GDM interventions are 
overlooked.6 Yet, subjecting all pregnant women to universal screening increases costs and may 
not be cost-effective relative to a risk factor–based approach.
In efforts to provide relevant information to decision makers in Singapore and other countries 
facing a similar dilemma, this study presents a model that compares the incremental cost- 
effectiveness of 3 GDM screening strategies: no screening, targeted screening based on risk fac-
tors, and universal screening. We hypothesize that universal screening is likely to be cost-effec-
tive relative to no screening or targeted screening.
Research Methods
Model Structure
A decision tree model was developed in TreeAge Pro 2013 (TreeAge Software, Williamstown, 
MA; Supplementary Figure 1 available at http://aph.sagepub.com/content/by/supplemental-data) 
to estimate the incremental cost-effectiveness of each strategy. No screening implies the lack of 
a systematic screening policy. The targeted screening approach follows the NICE guidelines, 
where only women with risk factors undergo 75 g OGTT. Specifically, NICE guidelines recom-
mend identifying pregnant women at high risk for GDM based on the following factors:
a. Prepregnancy body mass index ≥30 kg/m2
b. Previous macrosomic baby, defined as birth weight ≥90th weight percentile given that the 
standardized 4000 to 4500 g definition is not applicable for Asian newborns10
c. Previous history of GDM
d. First-degree relative with diabetes
e. South Asian (country of origin such as Bangladesh, India, Pakistan, Nepal, Bhutan, Mal-
dives, Myanmar, and Afghanistan), black Caribbean, or Middle Eastern ethnicity4
Under universal screening, all pregnant women receive a 75 g OGTT.
Based on the International Association of Diabetes and Pregnancy Study Group’s (IADPSG) 
diagnostic criteria, GDM is defined as a fasting plasma glucose (FPG) ≥5.1 mmol/L, a 75 g 
1-hour OGTT ≥10.0 mmol/L, or a 75 g 2-hour OGTT ≥8.5 mmol/L. GDM can be further divided 
into 2 groups:
 by guest on November 19, 2015aph.sagepub.comDownloaded from 
Chen et al 3
Category A: An entity introduced by Landon et al9 as mild GDM with FPG ≤5.3 mmol/L and 
at least 2 glucose measurements that exceed established thresholds taken at 2 different occa-
sions. Notably, the 2-hour measurement limit was set as 8.6 mmol/L.1,4 Because of the subse-
quent change in diagnostic criteria, we modified our criteria to a FPG ≤5.1 mmol/L and a 75 
g 2-hour OGTT ≥8.5 mmol/L.11
Category B: A group that encompasses mothers who have a FPG >5.1 mmol/L and a 75 g 
2-hour OGTT ≥8.5 mmol/L.
Based on the American Diabetes Association 2014 guidelines, all GDM patients are to receive 
dietary counseling from a certified dietician and perform home glucose monitoring.1 Patients 
with a FPG ≥7.0 mmol/L or a 75 g 2-hour OGTT ≥11.1 mmol/L are considered to have overt DM 
and require insulin injections as needed.12
Those who do not meet the criteria for any GDM category based on the IADPSG definitions 
do not receive additional follow-up. They or their offspring can still experience complications 
associated with GDM, albeit at a lower probability than those who test positive. The model 
includes complications for preeclampsia; delivery-related complications, including emergency 
or elective cesarean section; and fetal complications, including macrosomia, hypoglycemia, 
hyperbilirubinemia, shoulder dystocia resulting in temporary brachial palsy, neonatal intensive 
care unit (NICU) admission, and fetal death. For simplicity, all women in the model are assumed 
not to have diabetes mellitus prior to pregnancy (they would be screened regardless) and to be 
pregnant with their first child. The latter is a safe assumption for Singapore given the low fertility 
rate of 1.29 children per mother.13 Based on the current theory that overt DM patients may have 
had undiagnosed type 2 diabetes prior to pregnancy, women who receive an overt DM diagnosis 
on screening are assumed to convert to type 2 diabetes postdelivery.14
Probabilities and Prevalence Rates
All modeled probabilities and their data sources are shown in Table 1. The percentage of women 
who are assumed to test positive in universal screening (ie, the underlying prevalence of GDM) 
and percentages for those identified or missed by targeted screening were derived from the GUSTO 
(Growing Up in Singapore Towards healthy Outcomes) database, a birth cohort of 924 pregnant 
women who completed their entire pregnancy at the KK Women’s and Children’s Hospital (KKH) 
or National University Hospital, Singapore, between the years of 2009 and 2010 (of which 80% 
were in KKH), and who also received universal screening. Roughly one-third of babies born in 
Singapore are delivered at KKH and NUH. For an additional description of GUSTO participants, 
please see Supplementary Table 1 (available at http://aph.sagepub.com/content/by/supplemental-
data).15 Incidence rates for GDM-related perinatal complications were based on a literature review 
or the GUSTO data if no literature was available. For GDM-category specific rates where no 
information was available from either source, we computed an estimate assuming a linear relation-
ship in complication rates across GDM categories, as suggested by the Hyperglycemia and 
Adverse Pregnancy Outcomes (HAPO) study (see Table 1).16 For example, the average rates of 
macrosomia following screening and treatment are 1.74% for euglycemic patients (from GUSTO), 
5.9% for GDM-category A patients,9 and 10% for GDM-category B patients.7 We were not able to 
obtain the overt DM group’s macrosomia complication rate from the literature or the GUSTO 
cohort. Therefore, we linearly regressed the data available from GUSTO and the literature to gen-
erate a best-fit line of the form: complication rate (y) = 4.13x − 2.37, where x varies from 1 (GDM-
category A) to 4 (overt DM) and y is the complication rate. Using this equation, the overt DM 
macrosomia complication rate is estimated to be 14.13%. This approach was used to identify all 
perinatal complication rates for GDM-category A, GDM-category B, and overt DM.
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Table 1. Model Inputs.
Variables Treated
SourceProbabilities of Base Case (%) Sensitivity Range (%)
Universal screening
Test negative 90·72 a
Test positive 9·28 (0-25) a
 GDM–Category A 71·58 (10-75) a
 GDM–Category B 21·05 (10-25) a
 Overt DM 7·37 a
Targeted screening
 Screened/treated normal 38·97 (10-90) a
 Not screened/treated normal 61·03 a
 Screened/treated GDM–Category A 38·24 (10-90) a
 Not screened/treated GDM–Category A 61·77 a
 Screened/treated GDM–Category B 75·00 (10-90) a
 Not screened/treated GDM–Category B 25·00 a
 Screened/treated overt DM 57·14 (10-90) a
 Not screened/treated overt DM 42·86 a
Primary outcomes
Preeclampsia (treated)
 GDM–Category A 2·50 (0-8) Reference 9
 GDM–Category B 3·83 (0-9) b
 Overt DM 5·17 (0-10) b
Elective LSCS
 GDM–Category A 21·60 (0-30) a,bAdjusted via 
linear regression
 GDM–Category B 27·00 (0-40) a
 Overt DM 32·40 (0-50) a,bAdjusted via 
linear regression
Emergency LSCS
 GDM–Category A 14·40 (0-20) a,bExtrapolated via 
linear regression
 GDM–Category B 16·00 (0-25) Reference 7
 Overt DM 17·60 (0-30) bExtrapolated via 
linear regression
Birth weight >90 percentile
 GDM–Category A 5·90 (0-15) Reference 9
 GDM–Category B 10·00 (0-20) Reference 7
 Overt DM 14·13 (0-25) bExtrapolated via 
linear regression
Complications risk reduction percent from 
glucose management (%)
40 (20-60)  
Secondary outcomes
Neonatal hypoglycemia
 GDM–Category A 5·62 (0-10) Reference 22
 GDM-Category B 7·00 (0-15) Reference 7
 Overt DM 9·72 (0-18) bExtrapolated via 
linear regression
Hyperbilirubinemia
 GDM–Category A 8.14 (0-10) bExtrapolated via 
linear regression
(continued)
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Costs and Quality-Adjusted Life Year (QALY) Weights
Cost and QALY weights are shown in Table 2. For ease of exposition, all costs were converted 
from Singapore to US dollars.17 All costs used private patient rates, which approximate actual 
resource costs in Singapore, and were discounted at a rate of 3%. Baseline pregnancy costs were 
derived from KKH’s Obstetrics Clinic and Finance Office. For prenatal care, patients were 
assumed to have 10 clinic visits and received an antenatal package, blood group match, dating 
viability scan, and basic Down syndrome screening. Costs for newborn nursery care and photo-
therapy were derived from Ministry of Health’s 2013-2014 bill size information. Average man-
agement costs were derived from KKH’s Finance Office, ODAC Clinic, and Diets and Nutrition 
Clinic. The costs of delivery and adverse events were estimated based on 3106 maternal inpatient 
and 719 fetal discharge bills, respectively. Although none of these cases proved fatal, the costs 
for cases that ended in fatality in the model are assumed to be double the base case value.
Effectiveness is presented in terms of remaining quality-adjusted life years (QALYs) for both 
the mother and child postdelivery until death. QALY weights for maternal and fetal death were 
set to 0; uneventful vaginal deliveries are assumed to have no reduction in QALYs for mother or 
child. The mother is assumed to have 26.577 QALYs remaining and the child is assumed to have 
30.380 QALYs after discounting future QALYs at a rate of 3%. The impact of complications on 
the QALY weights and their duration for both mother and child were based on a literature review 
and/or expert input from a group of senior obstetricians and pediatricians at KKH (see Table 2 for 
citation sources).
Variables Treated
SourceProbabilities of Base Case (%) Sensitivity Range (%)
 GDM–Category B 9·00 (0-15) Reference 7
 Overt DM 11.48 (0-18) bExtrapolated via 
linear regression
NICU admissions
 GDM–Category A 5·71 (0-10) bExtrapolated via 
linear regression
 GDM–Category B 8·00 (0-15) Reference 7
 Overt DM 10·29 (0-20) bExtrapolated via 
linear regression
Fetal death
 GDM–Category A 0·2 (0-1) c
 GDM–Category B 0·2 (0-1) c
 Overt DM 0·2 (0-1) c
Birth trauma
 GDM–Category A 0·60 (0-2) Reference 9
 GDM–Category B 1·00 (0-5) Reference 7
 Overt DM 1·45 (0-10) bExtrapolated via 
linear regression
Abbreviations: DM, diabetes mellitus; GDM, gestational diabetes mellitus; LSCS, lower segment cesarean section; 
NICU, neonatal intensive care unit.
aGrowing Up in Singapore Towards healthy Outcomes (GUSTO) cohort data.
bEstimate from linear regression based on Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study’s main 
finding that there is a positive linear relationship between higher glucose values from oral glucose tolerance test 
results and adverse perinatal outcomes rates.2
cSingapore’s Ministry of Health Data.
Table 1. (continued)
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Table 2. Cost, QALY Variables, and Sources.
Cost Variables (Dollar)
Base Case Between 
2012 and 2013 (USD) Sensitivity Range (USD) Sources
Diagnostic test costs 34.34 (15-75) a
Prenatal care 2164.25 (1858-2470) a
 With euglycemia 0.00 b
 With GDM–Category A and B 537.73 (100-1,000) a
 With overt DM 7900.00 (5000-10 000) Reference 18
Primary and secondary outcomes
 Preeclampsia 1996.00 (998-1996) Reference 19
 Vaginal delivery 3860.21 (1057-26 373) a
 Elective LSCS 5978.41 (3119-19 572) a
 Emergency LSCS 7003.46 (3873-31 788) a
 Macrosomia additional delivery cost 206.22 (100-1000) a
 Newborn nursery care 549.15 90th percentile 900.395 b
 Fetal death Twice the cost of total 
resources used 2×
c
 Shoulder dystocia 5000.00 0-10 000 Reference 20
 Newborn baby (normal) with 
phototherapy
1132.49 90th percentile 
2580.295
b
 Hypoglycemia 2419.00 (500-10 000) a
 NICU admissions 3744.81 (752-16 256) a
QALY variables Value (Range Tested) Duration Sources
Discounted rate 0.03 (0.01-0.05) c
Life expectancy: mom (years) 54.00 b
Life expectancy: baby (years) 82.00 b
Healthy mom QALY weight 1.00 Entire life Reference 21
Healthy baby QALY weight 1.00 Entire life Reference 21
Primary outcomes QALY weight
 Preeclampsia 0.99 Entire life References 19, 
22, 23
 Maternal diabetes for overt DM only 0.80 Entire life Reference 24
 Normal vaginal delivery 1.00 Entire life c
 Elective LSCS 0.99 10 years c
 Emergency LSCS 0.95 10 years c
 Macrosomia 0.80 After age 55 years Reference 24
Secondary outcomes QALY weight
 Neonatal death–maternal 
perspective
0.92 10 years Reference 25
 Neonatal death–fetal perspective 0.00 Entire life c
 Shoulder dystocia and transient 
brachial plexus injury
0.99 4-5 months Reference 26
 Hyperbilirubinemia 0.70 1 week c
 Hypoglycemia 0.70 1 week c
 NICU admissions 0.50 2 months c
Abbreviations: DM, diabetes mellitus; GDM, gestational diabetes mellitus; LSCS, lower segment cesarean section; 
NICU, neonatal intensive care unit; QALY, quality-adjusted life year.
aKK Women’s and Children’s Hospital’s internal data.
bSingapore’s Ministry of Health Data.
cEstimated based on expert’s opinions.
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Benefits of Treatment
Randomized controlled trials on the effect of glycemic management on glucose intolerant women 
showed statistically significant risk reduction for primary outcomes such as preeclampsia, mac-
rosomia, and cesarean section. The risk reduction ranges from 20% to 60%.7,9 Therefore, inter-
vention effectiveness for complication rates was assumed to be a 40% reduction from the base 
case for all complications, with values ranging from 20% to 60% tested in sensitivity analyses.
Sensitivity Analyses
One-way sensitivity analyses varied the values of all input variables within a set range as shown in 
Table 1. Prevalence rates were set based on existing epidemiological data. All other input parame-
ters, aside from costs, were varied arbitrarily, but used ranges thought to include the most likely 
screening strategies. For costs, ranges were determined using KKH’s internal finance data. Key 
variables were analyzed jointly using 2-way sensitivity analyses. These variables, to which the 
model results were most sensitive, included GDM prevalence rate and intervention effectiveness. 
The discount rate was also varied between 1% and 5% to test the influence of this rate on the results.
Results
Applying the targeted screening guidelines to the GUSTO cohort revealed that 39.75% (n = 407) 
of pregnant women would receive OGTT; 6.4% (n = 26) would test positive for GDM-category 
A, 3.7% (n = 15) would test positive for GDM-category B, and roughly 1.0% (n = 4) would have 
overt diabetes. Relative to universal screening, the targeted approach would fail to identify 61.8% 
of GDM-category A cases, 25.0% of GDM-category B cases, and 42.9% of overt DM cases.
Base Case Cost-Effectiveness
The model (Supplementary Figure 1) predicts that universal screening would more than double 
the number of women correctly treated for GDM in Singapore: from 4390 women treated per 
100 000 pregnancies to 9200. It would further prevent approximately 977 cases of macrosomia. 
When converted to QALYs, the per capita additional QALYs gained from universal screening 
relative to targeted screening is 0.006 at an additional net cost, including the cost of screening, 
treatment, and reductions in costs for complications, of $64, resulting in an incremental cost-
effectiveness ratio (ICER) of $10 630/QALY gained. When comparing targeted screening to no 
screening, there is an improvement in QALYs of 0.007 at an additional cost of $59, resulting in 
an ICER of $9019/QALY gained. The movement from no screening to targeting screening, and 
from targeted to universal screening, generates similar incremental cost-effectiveness ratios.
Sensitivity Analyses
At the commonly applied cost-effectiveness threshold of $50 000/QALY,27 one-way sensitivity 
analyses revealed that varying any single variable associated with universal screening within 
reasonable sensitivity ranges does not increase the ICER beyond the threshold. Increases in inter-
vention effectiveness and/or a higher GDM prevalence reduce the ICERs for either targeted or 
universal screening, whereas higher screening or intervention costs increase the ICERS, as 
expected. Changes in the discount rate had little influence on the results. Supplementary Figure 
2 (http://aph.sagepub.com/content/by/supplemental-data) shows the results for the top 6 most 
influential variables. Remaining variables showed even smaller effects.
Cost-effectiveness acceptability curves reveal that, based on 10 000 simulations where all 
input parameters are varied based on their sensitivity ranges and using the $50 000 threshold for 
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cost-effectiveness, universal screening is incrementally cost-effective in 100% of simulations 
(Figure 1). Only when the willingness to pay (WTP) for increased QALYs drops to $10,000 is 
targeted screening the optimal choice, being chosen in 56% of simulations, whereas universal 
screening is optimal in 29% and no screening in 15%. Supplementary Figure 3 (http://aph.sage-
pub.com/content/by/supplemental-data), which presents the results of the 2-way sensitivity anal-
yses, reveals that universal screening is the preferred approach from a cost-effectiveness 
perspective when there exists a high rate of GDM in the population and/or when screening and 
treatment are reasonably effective. Targeted screening is rarely preferred because high rates of 
GDM and/or high effectiveness of treatment favors universal or no screening prior to screening 
and low GDM prevalence and/or low effectiveness favors a policy of no systematic screening.
Discussion
This study evaluated the incremental cost-effectiveness of three GDM screening strategies: no 
screening, targeted screening, and universal screening. In the base case, the ICER between no 
screening and targeted screening is $9019/QALY gained and the ICER between targeted screen-
ing and universal screening is $10 630/QALY gained, suggesting that under commonly accepted 
values for cost-effectiveness, universal screening is likely to be the optimal strategy for Singapore. 
Sensitivity analyses reveal that this conclusion holds under a range of assumptions of interven-
tion costs and effectiveness as well as changes in other key input parameters. Of note is that 
universal screening is likely to be cost-effective even when the prevalence of GDM among 
Figure 1. Cost-effectiveness acceptability curves from 100 000 Monte Carlo simulations. Results from 
100 000 trials of Monte Carlo simulation are consistent with the base case cost-effectiveness. Cost-
effectiveness acceptability curves reveal that, based on 10 000 simulations where all input parameters 
are varied based on their sensitivity ranges and using the $50 000 threshold for cost-effectiveness, 
universal screening is incrementally cost-effective in 100% of simulations. Only when the willingness to 
pay (WTP) for increased quality-adjusted life years (QALYs) drops to $10 000 is targeted screening the 
optimal choice, being chosen in 56% of simulations, whereas universal screening is optimal in 29%, and 
no screening in 15%.
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pregnant women is as low as 4% as long as interventions result in at least a 20% reduction in 
complication rates. For Singapore, universal screening will be cost-effective even if intervention 
is only 16% successful in reducing complications.
Prior to issuing their guidelines recommending targeted screening, NICE conducted a cost-
effectiveness analysis.4 However, their analysis was based on the 1999 World Health Organization 
diagnostic criteria,28 instead of the more recent IADPSG criteria.11 Regardless, as with our analy-
sis, they also found targeted screening to be highly cost-effective relative to no systematic screen-
ing; they generated an ICER of £3677/QALY gained (approximately $6251/QALY using July 26, 
2014 exchange rates of 1.70 US$ per £). Our analysis has several limitations. Because of a lack 
of comprehensive epidemiological studies documenting complication rates using the IADPSG’s 
diagnostic criteria, these rates were estimated based on a simple extrapolation method and the 
assumption from HAPO of a linear relationship between increasing OGTT values and complica-
tion rates.16 Although this relationship may not hold in all cases, our findings were robust to a 
range of assumptions for these values. Our study did not factor in the 1-hour threshold value, 
which is usually omitted in Singapore and several countries in the performance of glucose toler-
ance test with fasting and 2-hour plasma glucose tests for better patient compliance. A recent 
study in an Indian cohort of 1463 pregnant women demonstrated that adding a measurement of 
1-hour OGTT identified an additional 36 women (2.46%) and adding 2-hour OGTT measurement 
identified another 42 (2.87%) of their cohort, while the HAPO study showed that adding the 1-hour 
threshold identified an additional 5.7% of the population who did not have an elevated fasting value 
and adding the 2-hour threshold identified another additional 2.1% of the population.1,2 Thus, omit-
ting the 1-hour threshold while adding the 2-hour threshold would likely additionally identify 
less than 2% and 5% of the population who did not have an elevated fasting value.16,29 Including 
the 1-hour OGTT results would likely increase the prevalence rates of GDM slightly and make 
universal screening even more cost-effective. Other limitations are as follows: for simplicity, 
preterm labor was not incorporated into the model. Preterm labor increases delivery costs and 
babies tend to have longer duration of ICU stay and greater morbidity and mortality rates.30 Some 
fetal complications, including fetal renal vein thrombosis and stillborn, were excluded due to 
their rarity in Singapore. The model did not include the costs and health consequences of 
long-term maternal outcomes, including type 2 diabetes conversions for GDM-category A and B 
women. Inclusion of any of these factors would further favor universal over targeted or no 
screening.
It should be noted that we applied the NICE guidelines for targeted screening; other strategies 
would generate different results. The NICE approach applied to the GUSTO cohort picked up 
most of the GDM-category B group while missing large proportions of the GDM-category A and 
overt DM group. In fact, more than 40% of overt DM cases were missed, yet these are the most 
costly and severe cases.15 A targeted screening strategy that had significantly better sensitivity 
and specificity rates than the NICE approach might make no screening followed by universal 
screening less cost-effective, although it is unclear whether it would increase the ratio beyond 
accepted thresholds. This should be an area of future research.
In summary, our results suggest that, compared to targeted screening via the NICE guidelines, 
universal GDM screening is cost-effective for Singapore and likely so for other countries with 
comparable GDM rates and a similar ability to improve outcomes via early intervention.
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